Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation

Phase 3

Completed

• Conditions: Conjunctivitis; Allergy; Rhinitis

• Registration Number: NCT00623701
• Lead Sponsor: Allergopharma GmbH & Co. KG

Brief Summary

Efficacy and Safety from a high-dosed sublingual grass pollen preparation

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2008-02-19
• Study First Submitted QC: 2008-02-25
• Study First Posted: 2008-02-26
• Study Start: 2008-03
• Primary Completion: 2011-10
• Study Completion: 2012-10
• Status Verified: 2013-11
• Last Update Submitted: 2013-11-07
• Last Update Posted: 2013-11-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 126

Inclusion Criteria

• Allergic rhinoconjunctivitis attributable to grass pollen
• Positive SPT
• Positive EAST
• Positive provocation Test

Exclusion Criteria

• Serious chronic disease
• other perennial allergies

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Symptom and Medication Score	Grass pollen season 2009

Trial Locations

Locations (1)

Prof. Kristian Reich, MD; 🇩🇪 Hamburg, Germany